CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-18 | Morgan Leigh Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Sandor Victor Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Esposito Pamela Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2024-06-18 | Mainolfi Nello Chief Executive Officer | Exercise or conversion | +14,413 | $2.08 | $30K | 631,186 |
| 2024-06-18 | Mainolfi Nello Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −14,413 | 505,559 | ||
| 2024-06-13 | Booth Bruce Director | Sale 10b5-1 | −8,430 | $34.98 | $295K | 4,548,400 |
| 2024-06-13 | Booth Bruce Director | Sale 10b5-1 | −1,770 | $34.98 | $62K | 802,022 |
| 2024-06-12 | Booth Bruce Director | Sale 10b5-1 | −11,838 | $35.35 | $418K | 4,558,827 |
| 2024-06-12 | Booth Bruce Director | Sale 10b5-1 | −1,997 | $36.02 | $72K | 4,556,830 |
| 2024-06-12 | Booth Bruce Director | Sale 10b5-1 | −2,485 | $35.35 | $88K | 804,212 |
| 2024-06-12 | Booth Bruce Director | Sale 10b5-1 | −420 | $36.02 | $15K | 803,792 |
| 2024-06-07 | Horobin Joanna Director | Exercise or conversion 10b5-1 | +8,500 | $2.08 | $18K | 8,500 |
| 2024-06-07 | Horobin Joanna Director | Sale 10b5-1 | −2,187 | $32.65 | $71K | 6,313 |
| 2024-06-07 | Horobin Joanna Director | Sale 10b5-1 | −6,313 | $33.11 | $209K | 0 |
| 2024-06-07 | Horobin Joanna Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,500 | 33,195 | ||
| 2024-05-23 | Chadwick Jeremy G Chief Operating Officer | Sale | −2,575 | $34.99 | $90K | 44,183 |
| 2024-03-28 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2024-03-28 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy) | +32,000 | 32,000 | ||
| 2024-03-15 | Booth Bruce Director | Sale 10b5-1 | −8,126 | $39.31 | $319K | 4,621,849 |
| 2024-03-15 | Booth Bruce Director | Sale 10b5-1 | −49,591 | $40.62 | $2.0M | 4,572,258 |
Page 27 of 41 · 810 trades